Dispatches from Outsourcing in Clinical Trials East Coast, Philadelphia

Merck, Eisai Reap Savings from Off-Shoring, Outsourcing in China and India

By Zachary Brennan

- Last updated on GMT

Merck, Eisai Reap Savings from Off-Shoring in China and India
Drugmakers Merck & Co and Eisai have both substantially cut internal data management costs through two unique off-shoring operations in China and India, respectively.

Merck, which uses both outsourcing and off-shoring to expand its global reach, saw between 25% and 30% savings in its costs after establishing a data management centre in China, Dr. Peter Aurup, vice president of global clinical trial operations at Merck, said at the Outsourcing in Clinical Trials East Coast conference in Philadelphia on Tuesday.

The centre is staffed with about 95% local Chinese employees and about 5% foreign Merck staff that help to train the employees locally. Dr. Aurup said that “the biggest challenge​” is a high turnover rate, which has been about 20% in China and 25% in India. Trust is also a big issue, especially in terms of expectations when projects are handed over to local employees, he noted.

Merck Outsourcing

Between 2007 and 2008 Merck adopted a hybrid approach to outsourcing and off-shoring, Dr. Aurup said. “We’ve gone from outsourcing about 10% of our clinical trials in 2008 and 2009, to about 50% of trials now​,” he said. Trials for Merck’s biosimilar programs, as well as respiratory, diabetes and hypertension drugs in development are almost all being outsourced, he noted.

“Basically we have two ways to execute clinical trials: In-house management of a foreign site and fully outsourced trials through CROs​,” he said, noting that the decision to conduct a trial with in-house or outsourced staff is based on whether or not Merck has significant internal expertise in a particular therapeutic area or if there is an opportunity to learn from a partner.

Complex, novel compounds and studies with “soft” PRO (patient-reported outcome) or PRO-like primary endpoints are also most often developed in-house, Dr. Aurup added.

Outsourcing allows Merck “the necessary flexibility​” to adapt its pipeline to market conditions in a shorter amount of time, he said.

Eisai’s Experience in India

Eisai, meanwhile, established its global clinical data management centre in India through work with a single CRO there that is managed remotely by Eisai staff in New Jersey, Judy Villafranca, senior director of data operations and data management, said.

The company’s remotely-managed data centre in India, established in 2007, initially sought to reduce the company’s internal costs by 30%. Villafranca did not provide an estimate of how much the centre has saved Eisai but she said the cost savings have been “a tremendous eye-opener​.”

The key benefits of the centre include centralized data management, increased productivity, flexibility and innovation, she added.

 A centralized standards team in the US also collaborates with the centre in India, which has expanded to include more local contractors for “increased communications​,” she said. That team also ensures there are enough resources for oversight, and for process challenges to become quickly brought to their attention.

We want the India team to feel like they’re a part of the Eisai team​,” Villafranca added. 

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more